People · Operator
Named in public records as an officer, director or promoter · active 2014–2019 · Biotechnology, Pharmaceuticals, Other Technology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Vascugen, Inc. | — | Biotechnology | Series A | $10.0M | $361.5M | 2019 |
| Tacitus Therapeutics Inc. | — | Pharmaceuticals | Series A | $5.0M | $154.9M | 2019 |
| Flightstats, Inc. | — | Other Technology | Seed | $1.5M | $51.1M | 2014 |
Jeffrey Kennedy at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Jeffrey Kennedy on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Carter Cliff | 2 | 4 |
| Erik Lium | 1 | 3 |
| R. Tod Hutchinson | 1 | 1 |
| Mark Tilden | 1 | 1 |
| Marvin Yoder | 1 | 1 |
| Tom Novak | 1 | 1 |
| Thomas Novak | 1 | 1 |
| Eric Pappot | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.